retatrutide phase 2 study results Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 retatrutide type 2 diabetes phase
Pay in 4 interest-free payments of $6.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10












:max_bytes(150000):strip_icc()/Health-Stocksy-5080005-bb10491e0de9443eb957e3b7ecd8ef27.jpg)

















